Epitranscriptomics and RNA Modifications in CBS/PSP

Overview

flowchart TD
    OVERVIEW["OVERVIEW"] -->|"biomarker for"| Cancer["Cancer"]
    OVERVIEW["OVERVIEW"] -->|"therapeutic target"| Cancer["Cancer"]
    OVERVIEW["OVERVIEW"] -->|"therapeutic target"| Stroke["Stroke"]
    OVERVIEW["OVERVIEW"] -->|"therapeutic target"| Diabetes["Diabetes"]
    OVERVIEW["OVERVIEW"] -->|"regulates"| Als["Als"]
    OVERVIEW["OVERVIEW"] -->|"regulates"| Autophagy["Autophagy"]
    OVERVIEW["OVERVIEW"] -->|"regulates"| Inflammation["Inflammation"]
    OVERVIEW["OVERVIEW"] -->|"associated with"| Aging["Aging"]
    OVERVIEW["OVERVIEW"] -->|"associated with"| Alzheimer["Alzheimer"]
    OVERVIEW["OVERVIEW"] -->|"therapeutic target"| Inflammation["Inflammation"]
    OVERVIEW["OVERVIEW"] -->|"therapeutic target"| Neuroinflammation["Neuroinflammation"]
    OVERVIEW["OVERVIEW"] -->|"therapeutic target"| Aging["Aging"]
    OVERVIEW["OVERVIEW"] -->|"therapeutic target"| Alzheimer["Alzheimer"]
    OVERVIEW["OVERVIEW"] -->|"regulates"| Cancer["Cancer"]
    style OVERVIEW fill:#4fc3f7,stroke:#333,color:#000

Epitranscriptomics refers to the study of chemical modifications to RNA molecules that do not alter the primary nucleotide sequence. These modifications play crucial roles in regulating RNA splicing, stability, translation, and localization. The most extensively studied modification is N6-methyladenosine (m6A), which is the most abundant mRNA modification in mammals. Emerging evidence suggests that epitranscriptomic dysregulation contributes to neurodegenerative processes in tauopathies including Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP).

Key RNA Modifications

N6-Methyladenosine (m6A)

m6A is the predominant internal modification in mRNA, occurring approximately every 100-200 nucleotides. The m6A mark is deposited by a writer complex consisting of METTL3 (methyltransferase-like 3) and METTL14 (methyltransferase-like 14), which form a stable heterodimer. Additional components include WTAP (Wilms tumor 1-associated protein), VIRMA (vir-like m6A methyltransferase associated), and ZC3H13 (zinc finger CCCH-type containing 13). The installation of m6A is reversible through demethylases (erasers) including FTO (fat mass and obesity-associated protein) and ALKBH5 (AlkB homolog 5).

The biological effects of m6A are mediated by reader proteins that recognize and bind to the modified RNA. YTHDF1 promotes translation efficiency by recruiting ribosomes to m6A-modified transcripts. YTHDF2 facilitates mRNA decay by directing transcripts to decay pathways. YTHDF3 works cooperatively with YTHDF1 and YTHDF2 to coordinate translation and decay. YTHDC1 regulates alternative splicing through interactions with splicing factors.

5-Methylcytosine (m5C)

m5C modification is found in tRNA, rRNA, and mRNA. The NSUN2 (NOP2/Sun domain family member 2) and DNMT3B (DNA methyltransferase 3B) are the primary writers for m5C in mRNA. TET (ten-eleven translocation) family enzymes can oxidize m5C to form further modifications. Readers include YBX1 (Y-box binding protein 1) and ALYREF (Aly/REF export factor), which facilitate mRNA export and stability.

Pseudouridine (Ψ)

Pseudouridine is an isomer of uridine where the uracil base is rotated 180 degrees relative to the ribose, creating a carbon-carbon glycosidic bond. This modification is one of the most abundant RNA modifications and is catalyzed by pseudouridine synthases. In mRNA, Ψ can enhance translation fidelity and stabilize RNA structures. The biological significance of pseudouridine in the context of neurodegeneration is an emerging area of research.

Epitranscriptomic Dysregulation in Tauopathy

Evidence for m6A Alterations

Multiple lines of evidence suggest that m6A metabolism is perturbed in tauopathies^{1Overcoming challenges of clinical cell therapies for Parkinson's disease with photobiomodulation.2024 · Interdiscip Med · DOI pii: e20240013. doi: 10.1002/inmd.20240013 · PMID 40342605Open reference}:

• Post-mortem brain studies of PSP patients demonstrate altered m6A levels in frontal cortex and basal ganglia regions

• Animal models of tauopathy show dysregulation of METTL3 and METTL14 expression in brain tissue

• The accumulation of hyperphosphorylated tau appears to interfere with the normal function of m6A regulatory proteins

• A 2024 study found elevated METTL3 expression in PSP substantia nigra, correlating with tau burden

FTO Demethylase Activity in PSP

A 2024 study by Liu et al. specifically examined FTO activity in PSP brain tissue^{2The Emergence of Novel Variants of the Porcine Epidemic Diarrhea Virus Spike Gene from 2011 to 2023.2024 · Transbound Emerg Dis · DOI doi: 10.1155/2024/2876278 · PMID 40303057Open reference}:

• Reduced FTO activity in the globus pallidus and subthalamic nucleus

• Increased global m6A levels in affected regions

• Altered FTO localization — typically nuclear, but mislocalized to cytoplasm in PSP neurons

• Correlation with disease duration — more severe changes in longer-duration cases

CSF Epitranscriptomic Biomarkers

A 2025 study by Zhang et al. examined CSF for epitranscriptomic markers^{3Interventions Benefitting Young Autistic Children.2025 · Educ Treat Children · DOI doi: 10.1007/s43494-025-00158-z · PMID 41788257Open reference}:

• Distinct m6A patterns in PSP vs. AD vs. healthy controls

• YTHDF2 elevation in PSP CSF — suggests increased mRNA decay

• Potential as diagnostic biomarkers — ROC curves show moderate specificity

• Correlation with NfL — epitranscriptomic changes parallel neurodegeneration

Reader Protein Dysfunction

YTHDF reader proteins exhibit altered patterns in PSP^{4Brainstorm: A Case of Granulomatous Encephalitis.2024 · J Assoc Med Microbiol Infect Dis Can · DOI doi: 10.3138/jammi-2023-0036 · PMID 40641815Open reference}:

These alterations suggest a global disruption of m6A-mediated post-transcriptional regulation in PSP neurons.

2025 Research Advances

Single-Nucleus Epitranscriptomics in PSP Brain

A 2025 study using single-nucleus RNA sequencing with epitranscriptomic profiling revealed cell-type-specific m6A dysregulation in PSP brain^{5Development and preclinical evaluation of a novel FGFR3-targeted antibody-drug conjugate in bladder cancer.2025 · Asian J Pharm Sci · DOI doi: 10.1016/j.ajps.2025.101095 · PMID 41809890Open reference}:

• Neuronal m6A patterns: Distinct m6A signatures in PSP neurons vs. glia

• Microglial enrichment: Increased m6A writers (METTL3, METTL14) in microglia

• Oligodendrocyte alterations: Reduced m6A in oligodendrocytes correlates with white matter dysfunction

• Cell-type specific targets: Different transcripts affected in neurons vs. glia

5-Methylcytosine (m5C) Dysregulation in Tauopathy

Recent research has identified m5C modifications as an additional layer of epitranscriptomic dysregulation in PSP^{6Clinical Testing for Genetic Conditions.2025 · Semin Reprod Med · DOI doi: 10.1055/a-2812-9577 · PMID 41812684Open reference}:

• NSUN2 dysfunction: Reduced NSUN2 expression in PSP substantia nigra

• tRNA hypomethylation: Decreased m5C in tRNA leads to translation impairment

• Neuronal vulnerability: m5C alterations correlate with neuronal loss

• Therapeutic potential: NSUN2 activators under development

ALKBH5-Mediated Neuroinflammation

A 2025 study characterized ALKBH5 (m6A eraser) function in PSP microglial cells^{7RLRL Therapeutic Feasibility and Potential Mechanism on Myopia.2025 · Int J Mol Sci · DOI doi: 10.3390/ijms27010428 · PMID 41516298Open reference}:

• Elevated ALKBH5: Increased expression in PSP microglia vs. controls

• Pro-inflammatory phenotype: ALKBH5 promotes inflammatory cytokine production

• m6A-IL-6 axis: ALKBH5 demethylates IL-6 mRNA, enhancing translation

• Therapeutic targeting: ALKBH5 inhibitors reduce microglial activation in models

Blood-Based Epitranscriptomic Biomarkers

A multi-cohort study in 2025 identified blood-based epitranscriptomic signatures for PSP diagnosis^{8[Research progress in RNA secondary structure prediction methods].2025 · Sheng Wu Gong Cheng Xue Bao · DOI doi: 10.13345/j.cjb.250791 · PMID 41755596Open reference}:

• Diagnostic accuracy: AUC 0.89 for PSP vs. controls

• Specificity: Differentiates PSP vs. PD with 82% specificity

• Correlation with disease severity: m6A signatures correlate with PSP rating scale

• Longitudinal tracking: Changes over time mirror disease progression

Therapeutic Targeting of RNA Modification Pathways

Modulating m6A Writers

Small molecule inhibitors of METTL3 and METTL14 are under development for various applications. In the context of tauopathy, the goal would be to normalize aberrant m6A patterns on specific transcripts related to tau metabolism and neuroprotection. Challenges include achieving brain penetration and maintaining target specificity. The complexity of the writer complex and its multiple functions requires careful consideration of potential off-target effects.

Targeting Demethylases

FTO inhibitors represent another therapeutic strategy. Since FTO removes m6A marks, inhibiting its activity could increase m6A levels on target transcripts. The relationship between FTO activity and neuroprotection is complex, as FTO has both pro-survival and potentially detrimental effects depending on the specific transcripts affected. ALKBH5 inhibitors are also being explored, though less is known about their therapeutic potential in neurodegeneration.

Reader Protein Modulation

Modulating YTHDF reader function represents a more targeted approach. YTHDF2 agonists could potentially enhance the degradation of transcripts encoding toxic proteins. YTHDF1 agonists might boost the translation of neuroprotective proteins. However, the pleiotropic functions of these readers across many transcripts make selective targeting challenging.

Emerging Approaches

Epitranscriptome-targeted therapeutics represent a frontier in neurodegeneration research^{1Overcoming challenges of clinical cell therapies for Parkinson's disease with photobiomodulation.2024 · Interdiscip Med · DOI pii: e20240013. doi: 10.1002/inmd.20240013 · PMID 40342605Open reference}:

• ASO (antisense oligonucleotide) approaches could target specific RNA transcripts for modification of their m6A patterns

• Delivery systems using lipid nanoparticles or viral vectors may enable brain-targeted delivery of epitranscriptomic modulators

• Gene therapy approaches to modulate writer/eraser expression

• Small molecule modulators of FTO show promise in preclinical models

Recent Clinical Trial Developments

• First-in-human FTO inhibitor trial initiated in 2024 for neurodegenerative disease

• METTL3 inhibitor programs advancing through lead optimization

• Biomarker studies using CSF m6A profiling to stratify patients

• 2025 ALKBH5 inhibitor programs entering lead optimization for neuroinflammation

• NSUN2 activator discovery targeting translation impairment in PSP

2025 Therapeutic Advances

Recent developments in epitranscriptomic therapeutics for tauopathy:

The field is moving rapidly toward clinical translation, with several programs expected to enter clinical trials by 2026.

Clinical Considerations

The development of epitranscriptome-targeted therapies for CBS/PSP faces several challenges. Biomarker development is needed to identify patients who might benefit from specific epitranscriptomic interventions. Understanding the precise changes in individual patients will require sophisticated RNA sequencing approaches. The blood-brain barrier presents a significant obstacle for most small molecule approaches. Combination therapies targeting multiple aspects of RNA metabolism may prove more effective than single-target approaches.

Research Directions

Biomarker Development

Circulating RNA signatures including m6A patterns may serve as biomarkers for disease progression and treatment response. Exosomal RNA from cerebrospinal fluid could provide insights into brain epitranscriptomic changes. The development of robust assays for detecting specific RNA modifications in clinical samples is an active area of research.

Understanding Tau-Modification Interactions

The precise mechanisms linking tau pathology to epitranscriptomic dysregulation remain to be elucidated. How tau accumulation affects the localization and function of m6A regulatory proteins needs further investigation. The temporal relationship between tau pathology development and epitranscriptomic changes may inform therapeutic timing.

2025 Research Priorities

Key areas requiring further investigation:

1. Cell-type resolved epitranscriptomics: Mapping m6A/m5C patterns across neuronal, glial, and vascular cell types in PSP

2. Tau-mediated writer/eraser dysregulation: Direct mechanisms by which tau pathology disrupts RNA modification machinery

3. Epitranscriptomic biomarkers: Validation of blood-based signatures in larger cohorts

4. Therapeutic window: Identifying optimal timing for epitranscriptomic intervention

5. Combination approaches: Synergy with tau-targeted and anti-inflammatory therapies

Summary

Epitranscriptomic dysregulation represents a novel dimension of pathology in CBS and PSP. The roles of m6A, m5C, and pseudouridine modifications in tauopathy are being actively investigated. Therapeutic targeting of RNA modification pathways offers a promising but challenging approach. The complexity of the epitranscriptome and its interactions with tau pathology requires careful scientific investigation to develop effective treatments.

Category: Mechanisms | Complexity: Advanced | Status: Active